You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 34 No. 2, February 1977 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Therapeutic Usefulness of Propoxyphene Napsylate in Narcotic Addiction

Donald R. Jasinski, MD; Jeffry S. Pevnick, MD; Stewart C. Clark, MD, PhD; John D. Griffith, MD

Arch Gen Psychiatry. 1977;34(2):227-233.


Abstract

• The maximum doses of propoxyphene napsylate used to treat heroin addicts produce a degree of morphine-like activity equal to that produced by 20 to 25 mg/day of subcutaneously given morphine or 10 mg/day orally given methadone. This degree of activity would be sufficient to ameliorate abstinence even in patients dependent on large doses of narcotics—an observation that supports the utility of propoxyphene napsylate in detoxification. On the other hand, only patients taking 10 mg/day or less of parenterally administered heroin could be maintained on maximum subtoxic levels of propoxyphene napsylate without abstinence signs or symptoms suggesting that propoxyphene napsylate would be less useful in maintenance therapy.



Author Affiliations

From the Addiction Research Center, Division of Research, National Institute on Drug Abuse, Lexington, Ky. Dr Clark is now with the University of Calgary (Alberta) Faculty of Medicine.


Footnotes

Accepted for publication March 22, 1976.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clonidine in Morphine Withdrawal: Differential Effects on Signs and Symptoms
Jasinski et al.
Arch Gen Psychiatry 1985;42:1063-1066.
ABSTRACT  

Propoxyphene in Children With Iatrogenic Morphine Dependence: A Review of the Literature With Two Additional Cases
Hasday and Weintraub
Arch Pediatr Adolesc Med 1983;137:745-748.
ABSTRACT  

Propoxyphene for Maintenance Treatment of Narcotic Addiction
Woody et al.
Arch Gen Psychiatry 1981;38:898-900.
ABSTRACT  

Outpatient Treatment and Outcome of Prescription Drug Abuse
Tennant
Arch Intern Med 1979;139:154-156.
ABSTRACT  

Human Pharmacology and Abuse Potential of the Analgesic Buprenorphine: A Potential Agent for Treating Narcotic Addiction
Jasinski et al.
Arch Gen Psychiatry 1978;35:501-516.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1977 American Medical Association. All Rights Reserved.